The importance of being ncRNAs: From bit players as "junk DNA" to rising stars on the stage of the pharmaceutical industry

Annals of Translational Medicine

Volumn 5, Issue 6, 2017, Pages

  Di Mauro, Vittoria ^a,b,c   Catalucci, Daniele ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Milan Unit   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARGONAUTE 2 PROTEIN; BIOMATERIAL; DICER; MESSENGER RNA; MICRORNA; MICRORNA 21; RNA INDUCED SILENCING COMPLEX; UNTRANSLATED RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; HEART DEVELOPMENT; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OPEN READING FRAME;

EID: 85016296765     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.01.20     Document Type: Article

References (33)

1. Olson EN. A decade of discoveries in cardiac biology. Nat Med 2004; 10: 467-74.
2. Schonrock N, Harvey RP, Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res 2012; 111: 1349-62.
3. Kataoka M, Wang DZ. Non-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease. Cells 2014; 3: 883-98.
4. Frank S, Aguirre A, Hescheler J, et al. A lncRNA Perspective into (Re)Building the Heart. Front Cell Dev Biol 2016; 4: 128.
5. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-74.
6. Li N, Ponnusamy M, Li MP, et al. The Role of MicroRNA and LncRNA-MicroRNA Interactions in Regulating Ischemic Heart Disease. J Cardiovasc Pharmacol Ther 2016. [Epub ahead of print].
7. Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov 2017; 16: 167-79.
8. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 2001; 106: 23-34.
9. Hutvágner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001; 293: 834-8.
10. van Rooij E, Olson EN. microRNAs put their signatures on the heart. Physiol Genomics 2007; 31: 365-6.
11. Markham DW, Hill JA. MicroRNAs and heart failure diagnosis: MiR-acle or MiR-age? Circ Res 2010; 106: 1011-3.
12. Roberts TC. The MicroRNA Biology of the Mammalian Nucleus. Mol Ther Nucleic Acids 2014; 3: e188.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
14. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113: 676-89.
15. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-60.
16. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-8.
17. Castaldi A, Zaglia T, Di Mauro V, et al. MicroRNA-133 modulates the B1-adrenergic receptor transduction cascade. Circ Res 2014; 115: 273-83.
18. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
19. Skroblin P, Mayr M. "Going long": long non-coding RNAs as biomarkers. Circ Res 2014; 115: 607-9.
20. Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. Circ Res 2015; 116: 737-50.
21. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13: 622-38.
22. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721-6.
23. Gumireddy K, Young DD, Xiong X, et al. Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 2008; 47: 7482-4.
24. Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-9.
25. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-32.
26. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3.
27. Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 2012; 4: 3-14.
28. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012; 110: 496-507.
29. Viereck J, Kumarswamy R, Foinquinos A, et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 2016; 8: 326ra22.
30. Wheeler TM, Leger AJ, Pandey SK, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012; 488: 111-5.
31. Creemers EE, van Rooij E. Function and Therapeutic Potential of Noncoding RNAs in Cardiac Fibrosis. Circ Res 2016; 118: 108-18.
32. Singh S, Pandey VK, Tewari RP, et al. Nanoparticle based drug delivery system: Advantages and applications. Indian J Sci Technol 2011; 4: 177-80.
33. Di Mauro V, Iafisco M, Salvarani N, et al. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine (Lond) 2016; 11: 891-906.